超声介入聚桂醇硬化剂治疗肝囊肿疗效的分析

目的:探讨超声介入聚桂醇硬化剂治疗肝囊肿疗效的疗效。方法:将在我院76例被确诊为肝囊肿患者,随机分成治疗组(n=38)和对照组(n=38),治疗组在超声介入下囊肿内注入聚桂醇注射液,对照组采用乙醇治疗,比较两组住院时间、住院总费用、疗效以及不良反应。结果:治疗组患者抽出液(81.57±5.86)ml,对照组患者抽出液(91.71±7.80)ml,两组抽出液的差异有显著性(p0.05);治疗组和对照组患者住院时间分别为(4.86±0.90)天、(7.29±1.38)天,两组住院时间差异有显著性(P0.05);治疗组住院总费用为(4580.14±945.01)元,对照组患者住院总费用分别(4965.86±796.72)元;两组住院总费用差异无显著性(P0.05);治疗组总有效率为94.74%,对照组总有效率为81.58%,两组临床治疗效果差异有显著性(P0.05);两组患者不良反应发生例数无统计学差异(P0.05)。结论:聚桂醇作为新型硬化剂,疗效较好,不良反应少,可以成为囊肿超声介人治疗的首选硬化剂。

Analysis of the Efficacy of Ultrasound -Guided Lauromacrogol in the Treatment of Hepatic Cyst

Objective:to explore the clinical effect of ultrasound-guided lauromacrogol in the treatment of hepatic cyst.Methods:76 patients with hepatic cyst were divided randomly into two groups. The treating group(n=38) were treated with thelauromacrogol injection, while the control group (n=38) was given with ethanol. Comparing the curative effect, total cost, hospital stays and the side effect between two groups.Results:the extract in the treating group and control group is (81.57± 5.86)ml, (91.71± 7.80)ml respectively, which was statistical (P<0.05); the hospital stays in the treating group is (4.86± 0.90)d, which was statistical to compare that(7.29± 1.38) in the control group(P<0.05); however, there is no statistical difference comparing the total cost between two groups(P>0.05); the total effective rate in the treating group is 94.74%, which is higher than that (81.58%) in the control group(P<0.05); there was no statistical difference of the cases of side effect between two groups (P>0.05).Conclusion:Lauromacrogol is a new hardener characterized with good curative effect, less side effect, which can be the first choice to ultrasound intervention to treat hepatic cyst.